Introduction {#s1}
============

Lung transplantation is the final therapeutic option for patients with end-stage lung disease. COPD has been the most frequent underlying disease for both single (44% of all single lung transplants) and double (32% of all double lung transplants) transplant recipients from 1995 to 2016 \[[@C1]\].

Despite recent improvements in early post-operative outcomes, the median survival time following lung transplantation is approximately 5--6 years. In contrast with other lung diseases, *e.g.* idiopathic pulmonary fibrosis and pulmonary arterial hypertension, in which lung transplantation is believed to prolong life, the survival benefit is controversial for COPD because advanced-stage COPD outcomes using medical management alone are better than those of other end-stage lung diseases \[[@C2]--[@C6]\]. Despite advances in treatment, COPD mortality and prognosis have not changed appreciably in the last three decades. COPD continues to be the fourth most frequent cause of death worldwide \[[@C7]--[@C10]\].

A forced expiratory volume in 1 s (FEV~1~) \<30% of predicted was associated with survival rates of 65% and 30% at 2 and 5 years, respectively \[[@C11]--[@C13]\], and FEV~1~ below 30% was considered to be a threshold for lung transplant evaluation. Objective measurements like cardiopulmonary exercise test results or 6-min walk distance (6 MWD) were demonstrated to be consistent predictors of mortality \[[@C14], [@C15]\]. In an attempt to improve prediction of survival, the BODE index including body mass index (BMI), obstruction, dyspnoea and exercise capacity was developed by C[elli]{.smallcaps} *et al.* \[[@C16]\] in 2004.

Lung allocation scores (LAS) were implemented in May 2005 \[[@C17]\]. The models for survival after lung transplantation and wait list survival probability were combined to form a model in which the expected benefit of the transplant was calculated as the difference between predicted post-transplant survival and wait list survival \[[@C18]\]. The National Emphysema Treatment Trial (NETT) elucidated the risks and benefits of lung volume reduction surgery (LVRS) proposed as a therapy for advanced COPD in 2003 \[[@C19]\].

Our study compares COPD patient survival after lung transplantation with the survival of an independent series of severe emphysema patients who received only medical management (the control arm of NETT). We hypothesised that patients with severe COPD attain a survival benefit after lung transplantation and that parameters assessing the severity of disease, such as 6-min walk distance (6 MWD) and forced expiratory volume in 1 s (FEV~1~), are determinants of transplant benefit.

Material and methods {#s2}
====================

The University of Maryland Baltimore Institutional Review Board granted the study an exemption (HP-00068606) from informed consent for review of data from UNOS (the United Network for Organ Sharing) and NETT.

We present patient characteristics for the following three groups obtained from the UNOS and NETT data files: UNOS patients listed for lung transplantation in the LAS era, UNOS patients transplanted in the LAS era and NETT patients randomised to the control arm of the trial (to receive only pulmonary rehabilitation and standard medical therapy).

For continuous variables, medians and interquartile ranges were compared with Wilcoxon rank-sum tests, as statistical tests for normality (including Shapiro--Wilk and Kolmogorov--Smirnov) rejected normality of distributions for several variables. Categorical variables, frequency distributions were analysed using chi-squared tests. We compared baseline characteristics of the UNOS transplanted patients and NETT control patients; we did not make a separate comparison of UNOS listed and NETT rehabilitation group patients' baseline characteristics because UNOS listed and UNOS transplanted patients had a large overlap and were very similar in the baseline characteristics we assessed.

We first compared transplant-free survival between all UNOS listed patients (censoring transplanted patients at the time of surgery) and NETT control patients. Our primary analyses compared post-transplant survival for UNOS transplanted patients to survival after randomisation for NETT control patients. Re-transplantation for UNOS patients and transplantation following randomisation for NETT patients were taken to be treatment failures. In UNOS, deaths of the study participants were ascertained *via* the US Social Security Death Index. Patients were followed for a maximum of 10 years after transplantation or randomisation and were censored if alive and free of subsequent transplantation at the end of follow-up. NETT patients underwent complete evaluations at 6 months, 12 months, and yearly thereafter.

A propensity score was computed for each patient in the UNOS COPD and NETT patient population, using a logistic regression model that included the following parameters, selected based on clinical relevance and literature review \[[@C11]--[@C16]\]: age, sex, percent predicted of FEV~1~, percent predicted of forced vital capacity (FVC), 6 MWD, oxygen requirements, carbon dioxide tension (*P*~CO~2~~) and body mass index (BMI). UNOS patients were excluded if they had values outside ranges based on eligibility criteria for NETT and plausibility for COPD transplant patients: 18≤age≤80 years, 5≤FEV~1~≤45% predicted, 10≤FVC≤100% predicted, 6 MWD≥140 m (459 ft.), 0≤O~2~ requirements≤6 L per min., 25≤Partial pressure of carbon dioxide (*P*~aCO~2~~)≤60 mmHg, mean pulmonary artery pressure (PAP)≤35 mmHg, and 15≤BMI≤31.1 kg·m^−2^ for females and 32.2 kg·m^−2^ for males. A greedy matching algorithm implemented *via* the gmatch SAS macro was used to match patients between NETT and UNOS based on the propensity score, with one-to-many matching.

The log-rank test was used for survival analyses, and the Renyi test when survival curves crossed. Survival comparisons between UNOS transplanted and NETT patients were repeated after stratifying patients by 6 MWD and FEV~1~, and post-transplant survival was compared between the full populations of "more severe" (6 MWD \<1000 ft (∼300 m) or FEV~1~ \<20% predicted) and "less severe" (6 MWD ≥1000 ft (∼300 m) and FEV~1~ ≥20% predicted) transplanted COPD patients in UNOS. The decision to use cut-offs of 20% for FEV~1~ and 1000 ft (∼300 m) for 6 MWD was based on clinical experience. The most recent ISHLT consensus document recommend a FEV~1~ less than 15% to 20% predicted as criteria for lung transplant listing \[[@C20]\]. Similarly, a 6 MWD less than 1000 ft (∼300 m) was associated with increased mortality in 1-year experience \[[@C21]\].

Analyses were conducted with SAS Software, version 9.4, and p\<0.05 (two-tailed) statistically significant.

Results {#s3}
=======

We identified 4521 COPD patients in the UNOS dataset who received a transplant between May 2005 and August 2016; 5938 COPD patients were listed for transplantation in this same era. 604 patients were randomised to pulmonary rehabilitation and medical treatment in the NETT between January 1998 and July 2002. Demographic and clinical characteristics for the three populations (UNOS listed, UNOS transplanted and NETT control) are shown in [table 1](#TB1){ref-type="table"}.

###### 

Patient characteristics at baseline

                                                       **UNOS listed**      **Unmatched Patients**   **NETT control**       **p-value^¶^**   **Matched Patients**   ****NETT control3****   **p-value**
  ---------------------------------------------------- -------------------- ------------------------ ---------------------- ---------------- ---------------------- ----------------------- -------------
  **Subjects n**                                       5938                 4521                     604                                     401                    262                     
  **Demographics**                                                                                                                                                                          
   Age years                                           61 (56--64)          61 (57--65)              67 (64--71)            \<0.0001         64 (61--67)            65 (61--68)             0.02
    ≥65                                                1445 (24)            1287 (28)                432 (72)               \<0.0001         199 (50)               152 (58)                0.04
   Female sex                                          3043 (51)            2182 (48)                219 (36)               \<0.0001         177 (44)               109 (42)                0.52
   Race                                                                                                                     0.10                                                            0.28
     White                                             5462 (92)            4172 (92)                569 (94)                                384 (96)               246 (94)                
     Non-white                                         476 (8)              349 (8)                  35 (6)                                  17 (4)                 16 (6)                  
   BMI kg·m^−2^                                        24 (21--28)^\#^      24 (21--27)^\#^          25 (22--27)^\#^        0.12             25 (22--27)            24 (21--28)             0.76
  **Disease severity**                                                                                                                                                                      
   FVC % pred                                          54 (43--65)^\#^      52 (41--64)^\#^          58 (48--68)^\#^        \<0.0001         55(47--65)             55 (45--65)             0.92
   FEV~1~ % pred                                       20 (16--25)^\#^      20 (16--25)^\#^          24 (20--29)^\#^        \<0.0001         21 (18--25)            22 (18--26)             0.10
   6 MWD ft                                            760 (497--984)^\#^   770 (504--998)^\#^       1229 (990--1413)^\#^   \<0.0001         1000 (810--1191)       1065 (860--1280)        0.01
   6 MWD m                                             232 (151--300)^\#^   235 (154--304)^\#^       375 (302--431)^\#^     305 (247--363)   325 (262--390)                                 
   6 MWD \<1000 ft (∼300 metre) or FEV~1~ \<20% pred   4035 (86)^\#^        4004 (89)^\#^            238 (39)               \<0.0001         269 (67)               151 (58)                0.02
   O~2~ requirements at rest L                         3 (2--3)^\#^         3 (2--4)^\#^             1 (0--2)               \<0.0001         2 (2--3)               2 (2--2)                0.04
   *P*~CO~2~~ mmHg                                     47 (42--54)^\#^      49 (43--58)^\#^          43 (39--46)            \<0.0001         45 (40--50)            44 (40--49)             0.49
   Mean PAP ≥35 mmHg                                   555 (10)^\#^         455 (11)^\#^             0 (0)^+^                                0 (0)^+^               0 (0)^+^                
  **Transplant characteristics**                                                                                                                                                            
   Type of lung transplant                                                                                                                                                                  
    Single                                             NA                   1756 (39)^\#^            NA                                      183 (46)               NA                      
    Double                                             NA                   2764 (61)^\#^            NA                                      218 (54)               NA                      

Data are presented as median (interquartile range) or n (%), unless otherwise stated. UNOS: United Network for Organ Sharing; NETT: National Emphysema Treatment Trial; BMI: body mass index; FVC: forced vital capacity; FEV~1~: forced expiratory volume in 1 s; 6MWD: 6-min walk distance; *P*~CO~2~~: carbon dioxide tension; PAP: pulmonary arterial pressure. NA: not applicable. ^\#^: At least one patient was missing data on this variable, so statistics are based on patients with available data; ^¶^: p-value is for the comparison of the UNOS transplanted and NETT control groups; ^+^: mean PAP≥35 was an exclusion criterion for NETT, so prior to matching, we excluded patients with PAP≥35.

A Kaplan--Meier plot comparing transplant-free survival between the UNOS listed (censoring transplanted patients at the time of surgery) and NETT control populations is shown in [figure 1](#F1){ref-type="fig"}. Median survival without transplantation was 5.2 years in the NETT population and 4.7 years in the UNOS listed population (log rank p=0.01).

![Kaplan--Meier plot of transplant-free survival for United Network for Organ Sharing (UNOS) listed and National Emphysema Treatment Trial (NETT) patients.](00177-2019.01){#F1}

After excluding patients with missing data on one or more of the variables to be used for propensity score matching, excluding patients whose values on at least one of these variables were inconsistent with NETT eligibility criteria or untenable for a COPD transplant patient, and matching the remaining UNOS transplanted and NETT control patients, there were 262 patients from NETT and 401 patients from UNOS. [Figure 2](#F2){ref-type="fig"} contains a Kaplan--Meier plot comparing survival between the matched UNOS transplanted and NETT control patients. The median (IQR) survival free of subsequent transplantation was 4.0 years (2.2--6.6 years) in NETT, compared 5.1 years (1.9--10.1 years) in UNOS (log rank p=0.003). In the first 2 years after transplantation or randomisation, the probability of survival was similar for UNOS patients and NETT patients, (74% *versus* 77%; p=0.28). Around 2.5 years the survival curves cross. Since the survival crossed, the Renyi test was performed for comparison of survival between the two groups (p\<0.0001).

![Kaplan--Meier plot of survival curves for propensity-matched United Network for Organ Sharing (UNOS) transplant patients and National Emphysema Treatment Trial (NETT) patients.](00177-2019.02){#F2}

The crossing NETT and UNOS survival curves suggest the possibility of heterogeneity in the benefit of transplant (*e.g.* a trade off of perioperative mortality against a long-term survival improvement). When we stratified patients according to disease severity as indicated by 6 MWD and FEV~1~, out of the 4496 UNOS transplanted patients who had 6 MWD and FEV~1~ data available, 89% (4004) were in the more severe stratum, and 11% (496) were in the less severe stratum.

Within each disease severity stratum, a Kaplan--Meier plot comparing survival between matched UNOS transplanted and NETT patients is shown in [figure 3](#F3){ref-type="fig"}. In the more severe stratum, median (IQR) survival among the matched patients was 5.0 years (1.9--10.1 years) for UNOS transplanted patients and 3.4 years (1.9--5.5 years) for NETT patients; log-rank p\<0.0001 and Renyi p\<0.0001. In the less severe stratum, median survival was 5.4 years (1.8--9.2 years) for UNOS, and 4.9 years (2.6--7.9 years) for NETT; log-rank p=0.73, Renyi p=0.61. The test for heterogeneity between these two strata was significant at p=0.01.

![Kaplan--Meier plot of survival curves for propensity-matched United Network for Organ Sharing (UNOS) transplant patients and National Emphysema Treatment Trial (NETT) patients, within each disease severity stratum. FEV~1~: forced expiratory volume in 1 s.](00177-2019.03){#F3}

Survival percentages at each year were calculated ([fig. 3](#F3){ref-type="fig"}). For patients with a FEV~1~ ≤20% predicted and 6 MWD ≤1000 ft (∼300 m), a survival benefit of transplantation was apparent after 2 years, while for patients with FEV~1~ \>20% predicted and 6 MWD \>1000 ft (∼300 m), transplantation did not appear to confer a survival advantage.

The finding of survival benefit in patients with low FEV~1~ or 6 MWD undergoing lung transplantation is not unique to the \<20% predicted FEV~1~ and \<1000 ft (∼300 m) 6 MWD demarcations, as we found the benefit is even stronger among more severe patients with FEV~1~ \<15% predicted or \<800 ft (∼240 m) for the 6 MWD.

As shown in [figure 4](#F4){ref-type="fig"}, there was little difference in post-transplant survival according to disease severity stratum. Among the 4496 transplanted UNOS patients: median survival was 5.5 years in the more severe stratum, compared with 5.7 years in the less severe stratum (p=0.77). The median (IQR) LAS differed by 1.2 units between patients in the more severe stratum (33.6 (32.6--35.4)) and the less severe stratum (32.4 (31.7--33.5)); p\<0.0001. The same trend was observed within the transplanted patients who were propensity-matched to NETT patients. The median (IQR) LAS differed by only 0.5 units between transplanted patients in the more severe stratum (32.7 (31.9--33.7)) and the less severe stratum (32.2 (31.6--33.4)) indicating non-clinical significance for LAS but statistical significance; p\<0.008.

![Kaplan--Meier plot comparing post-transplant survival between pre-operative disease severity strata. 6MWD: 6-min walking distance; FEV~1~: forced expiratory volume in 1 s.](00177-2019.04){#F4}

Discussion {#s4}
==========

COPD is one of the most common indications for lung transplantation \[[@C1], [@C3]\], but there is a continuing controversy regarding the survival benefit of this intervention for COPD patients. Various studies have reported a clear impact on life expectancy after lung transplantation for idiopathic pulmonary fibrosis, cystic fibrosis and primary pulmonary hypertension \[[@C3], [@C22]--[@C25]\]; reports for COPD patients are inconsistent \[[@C26], [@C27]\].

A retrospective cohort study of 1997 patients transplanted in the UK demonstrated that transplantation confers survival benefit for patients with emphysema \[[@C25]\], results consistent with earlier European studies \[[@C23], [@C24]\]. In contrast, H[osenpud]{.smallcaps} *et al.* \[[@C28]\], in a 1998 study reviewing the outcomes of 1274 lung transplant candidates found mortality for COPD patients on the waiting list was low; post-transplantation survival did not exceed waiting-list survival during the 2-year follow-up. T[habut]{.smallcaps} *et al.* \[[@C29]\] in 2008 used the UNOS transplant and waitlist data to estimate the survival impact of lung transplant and reported that patients with an FEV~1~ \<16% of predicted will gain at least 1 year of survival after transplant. In these studies, mortality after lung transplant is compared to mortality of potential recipients with COPD on a lung transplant waiting list who are not operated or censored at the time of operation. Those analyses are subject to potential selection bias.

To clarify the survival benefit of lung transplantation for COPD patients without this selection bias, we analysed survival data from the UNOS Thoracic Registry and compared it to survival in the control group of NETT, an independent COPD population. Initially, we performed a survival comparison of all UNOS listed patients and the NETT control cohort, censoring UNOS listed patients at the time if transplantation, to establish that the two populations are comparable (5.2 years in NETT *versus* 4.7 years in UNOS). This analysis suggested that the populations of NETT and UNOS listed patients (censored at transplantation) are comparable for survival even though baseline characteristics indicated the NETT population was less severely ill; propensity score matched analysis seem reasonable.

Consistent with H[osenpud]{.smallcaps} *et al.* \[[@C28]\], in the first 2 years following transplantation or NETT randomisation, we found a similar survival in the UNOS (74%) and NETT (77%) groups, a difference that was not statistically significant (p=0.28). Patients undergoing lung transplantation experience immediate risks related to the procedure in exchange for the possibility of relief of symptoms and survival gains. The "crossing" NETT and UNOS survival curves are difficult to interpret and suggest both the possibility of long-term benefit and heterogeneity in the benefit of transplant. Therefore, we stratified patients according to disease severity as indicated by 6 MWD and FEV~1~.

Although the curves cross still for the "more severe" stratum in the stratified analysis, they are closer together. There was a survival advantage for UNOS lung transplant patients compared to NETT patients among those with "more severe" COPD, as defined by 6 MWD \<1000 ft (∼300 m). or FEV~1~ \<20% predicted. A large majority of transplanted patients in UNOS (89%) were in the "more severe" category.

Less severely affected patients (6 MWD ≥1000 ft (∼300 m) and FEV~1~ ≥20% of predicted), 11% of transplanted patients in UNOS, showed little if any increase in survival with lung transplantation. For these patients, on a case-by-case basis, there may be other clinical or functional reasons that suggest urgency of lung transplantation.

The difference in LAS scores between the "more severe" and "less severe" strata was small in spite of the clear difference in survival benefit of transplantation, suggesting that for COPD patients, the LAS score may not reflect post-transplant survival benefit. A composite index of clinical parameters able to predict post-transplant surgery survival is urgently needed.

There is a difference of a decade in the observation on NETT patients and the UNOS patients we report; but, COPD mortality and prognosis have not changed substantially in the last 3 decades. Specific therapies (like new inhalers or endobronchial valves placement) have had some impact on quality of life but none other than transplantation on survival \[[@C30]\].

UNOS does not contain quality of life information, and this outcome was not assessed in our study. Because UNOS does not quantify dyspnoea, we were not able to calculate the BODE (BMI, airflow obstruction, dyspnoea, exercise capacity) index for UNOS patients. However, the criteria of 6 MWD \<1000 ft (∼300 m) or FEV~1~ \<20% of predicted are consistent with the recent International Society for Heart and Lung Transplantation (ISHLT) consensus that proposes a BODE threshold≥7, which represents a low FEV~1~ and 6 MWD, for transplant listing \[[@C28]\].

The study has limitations associated with the retrospective nature of the UNOS data. A considerable proportion of transplanted patients had to be excluded because they did not meet the NETT inclusion criteria; *e.g.* patients with low 6 MWD (459 ft (∼140 m)), severe pulmonary hypertension (\>35 mmHg) or high oxygen requirements (\>6 L·min^−1^).But our comparison in this limited population should generalise well because the more severely affected patients will almost surely benefit from surgery unless they are among the infrequent perioperative mortality cases and the less severely affected will do better than without surgery. Our results suggest that perioperative mortality is similar for the less severely affected COPD patients and the more severely affected patients who would sustain the most benefit from transplant.

Although the results could not be extended to all COPD patients listed for transplantation, our study suggests that more severe COPD cases are better candidates for lung transplantation when survival is the primary outcome measure not taking into account quality-of-life assessment. The retrospective nature of UNOS data does not allow quality-of-life assessment as this information is not recorded in UNOS database. A comparison of post-transplant survival between the more severe and less severe COPD patients indicated that post-transplant survival is similar regardless of disease severity among COPD patients, refuting the common argument that more severe patients are too high risk for transplantation with surgery increasing death risk in more ill patients. Differences in survival benefit between the disease severity strata are due to the favourable survival of less severely affected COPD patients even without transplantation treated with medical therapy and pulmonary rehabilitation according to NETT criteria. These results should be generalised with some caution because the NETT patients were selected to meet all enrollment criteria for that clinical trial.

Conclusion {#s4a}
----------

We conclude that transplant surgery has a survival benefit in the more severely affected end-stage COPD patients (with 6 MWD \<1000 ft (∼300 m) or FEV~1~ \<20%), and, no appreciable benefit for the less severely affected patients. 6 MWD and FEV~1~ contributes to the clinical decision-making process for pulmonologists and thoracic surgeons evaluating end-stage COPD patients.
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